Latest
Recommended
Published: Thu, August 11, 2016
Economy | By Melissa Porter

Valeant Pharmaceuticals Intl (NYSE:VRX) & Novavax, Inc

Valeant Pharmaceuticals Intl (NYSE:VRX) & Novavax, Inc

(NYSE:W) is $54.08 while analysts mean recommendation is 2.30. According to these analysts, the Low Revenue Estimate for Aralez Pharmaceuticals Inc.is 11000 and the High Revenue Estimate is 12500. Canaccord Genuity's price target indicates a potential downside of 0.57% from the stock's current price. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The company's price sits 20.93% above from its 50-day moving average of $22.34 and -51.50% below from the stock's 200-day moving average of $40.98. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -72.30%.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) holds the market capitalization of $9.82B along with 341.19M outstanding shares.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) jumped 25.43% to reach at $28.16 during the course of session. Valeant said that its earnings per share and revenue estimates for the year would remain steady, however, reassuring investors. Analysts had expected the company to post earnings of $1.48 per share on $2.46 billion in revenue, according to a Thomson Reuters consensus estimate. During the same quarter in the prior year, the firm posted $2.14 earnings per share. Revenue was $2.42 billion, an 11% drop. slid 11% to $2.42 billion. 2016 Guidance Unchanged and It Remains Back Loaded; Can Mgt Deliver Despite Some Clear Headwinds?: Despite the Q2 miss relative to consensus, mgt maintained its full year rev & EPS guidance of $9.9-10.1B and $6.60-$7.00.

Other hedge funds recently made changes to their positions in the company. Riggs Asset Managment Co.

Medivation stated a GAAP net loss of $403.9 million, or $2.45 per diluted share, for the quarter ended June 30, 2016, contrast with GAAP net income of $25.8 million, or $0.15 per diluted share, for the same period in 2015.

Shares of Novavax, Inc. Acrospire Investment Management LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at approximately $108,000. The company holds earnings per share of -0.78 for the twelve months. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company's stock valued at $350,000 after buying an additional 627 shares during the period. Seven Bridges Advisors LLC now owns 41,393 shares of the specialty pharmaceutical company's stock valued at $833,000 after buying an additional 890 shares during the period. The transaction was executed at $24.4 per share with total amount equaling $97,600. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Mizuho reissued an "underperform" rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Royal Bank Of Canada reissued a "sector perform" rating and issued a $65.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Monday, May 9th.

Piper Jaffray reiterated Neutral rating but has raised price target to $22 from $19.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Like this: